Estimating the Lifetime Benefits of Treatments for Heart Failure.

ABSTRACT:

Objectives

This study compared ways of describing treatment effects. The objective was to better explain to clinicians and patients what they might expect from a given treatment, not only in terms of relative and absolute risk reduction, but also in projections of long-term survival.

Background

The restricted mean survival time (RMST) can be used to estimate of long-term survival, providing a complementary approach to more conventional metrics (e.g., absolute and relative risk), which may suggest greater benefits of therapy in high-risk patients compared with low-risk patients.

Methods

Relative and absolute risk, as well as the RMST, were calculated in heart failure with reduced ejection fraction (HFrEF) trials.

Results

As examples, in the RALES trial (more sev

SUBMITTER: Ferreira JP 

PROVIDER: S-EPMC7720789 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature